A phase I trial of In-111-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer
Автори: | Vallis, K, Reilly, R, Scollard, D, Merante, P, Freeman, M, Lockwood, G, Sabate, K, Brade, A |
---|---|
Формат: | Conference item |
Опубліковано: |
2008
|
Схожі ресурси
Схожі ресурси
-
Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.
за авторством: Vallis, K, та інші
Опубліковано: (2014) -
A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer
за авторством: Vallis, K, та інші
Опубліковано: (2005) -
Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
за авторством: Reilly, R, та інші
Опубліковано: (2006) -
Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
за авторством: Hu, M, та інші
Опубліковано: (2007) -
Amplified delivery of indium-111 to EGFR-positive human breast cancer cells.
за авторством: Wang, J, та інші
Опубліковано: (2001)